SCHEMBL1574971

SCHEMBL1574971

Cc1cccc(NC(=O)N2CC(N(C)C)C2)c1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.63
RAB9A P51151 3/20 0.62
GRIN2B Q13224 1/20 0.55
FAAH O00519 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.50
NLRP3 Q96P20 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MAPT P10636 2/20 0.49
LMNA P02545 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.47
POLB P06746 1/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574682 0.86 ALDH1A1 (0.56) ALDH1A1RAB9AGRIN2BFAAHSMN1; SMN2
SCHEMBL1575143 0.85 MAPT (0.48) ALDH1A1RAB9AMAPTLMNANPSR1
SCHEMBL1574828 0.85 ALDH1A1 (0.59) ALDH1A1RAB9AGRIN2BFAAHSMN1; SMN2
SCHEMBL1573328 0.85 ALDH1A1 (0.59) ALDH1A1RAB9AGRIN2BFAAHSMN1; SMN2
SCHEMBL1574407 0.85 ALDH1A1 (0.62) ALDH1A1RAB9AGRIN2BSMN1; SMN2MAPT
SCHEMBL1575047 0.85 CYP2D6 (0.55) ALDH1A1SMN1; SMN2MAPTPOLBNPC1
SCHEMBL1574656 0.83 ALDH1A1 (0.56) ALDH1A1RAB9AGRIN2BFAAHSMN1; SMN2
SCHEMBL1573940 0.83 ALDH1A1 (0.56) ALDH1A1RAB9AGRIN2BFAAHSMN1; SMN2
SCHEMBL1575307 0.83 MAPT (0.63) ALDH1A1RAB9ASMN1; SMN2HSD17B10MAPT
SCHEMBL1574748 0.83 GRIN2B (0.63) RAB9AGRIN2BMAPTLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB ALDH1A1 1445/4885RAB9A 898/4885GRIN2B 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.